Skip to content
You are now leaving to visit

Ionis’ Factor XI anti-thrombotic medicine advances with Bayer following positive clinical results

  CARLSBAD, Calif. , Oct. 9, 2019 /PRNewswire/ —           IONIS-FXI-L Rx , Ionis’ first-in-class FXI anti-thromboticmedicine, to potentially treat millions of patients globally     Ionis Pharmaceuticals, Inc. (NASDAQ: IONS), the leader in RNA-targeted therapeutics, announced today that the